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KwaZulu-Natal, South Africa, with high HIV burden, 
in the HIPSS study: a household-based complex multilevel 
community survey
Anneke Grobler, Cherie Cawood, David Khanyile, Adrian Puren, Ayesha B M Kharsany
Summary
Background With the goal of eliminating new HIV infections, UNAIDS set the ambitious 90-90-90 targets to be 
achieved by 2020. We assessed whether these targets are being met among participants of the HIV Incidence 
Provincial Surveillance System (HIPSS) in a high-burden district of South Africa.
Methods We used data from a HIPSS household-based, cross-sectional survey of HIV prevalence and incidence done in 
the uMgungundlovu district, KwaZulu-Natal, in 2014 and 2015. In randomly selected enumeration areas, 50 households 
were drawn systematically along a serpentine pattern from a random start point. One eligible individual in each household 
was asked to provide blood for HIV testing and to complete a questionnaire. If a household refused to participate, the 
house next to it was approached. Eligible participants were aged 15–49 years, lived in the household, were not planning to 
move away, and spoke English or Zulu. Viral load was measured in samples positive for HIV. We also assessed participants’ 
HIV linkage to care and treatment. Data were population weighted to allow for multilevel sampling and non-response.
Findings 9812 participants were enrolled, 3547 men (36%) and 6265 women (64%). Overall, 504 of 1014 men 
(estimate 52%, 95% CI 47–56) and 1833 of 2955 women (65%, 62–67) who were HIV positive knew their HIV status. 
Of those who knew, 344 of 522 men (69%, 63–75) and 1254 of 1845 women (70%, 68–73) were taking ART. Among 
recipients of ART, 294 of 341 men (85%, 80–90) and 1117 of 1249 women (90%, 87–92) had viral loads less than 
1000 copies per mL. Among all HIV-positive participants, 427 of 1014 men (44%, 39–49) and 1680 of 2955 women 
(58%, 55–61) had viral loads lower than 1000 copies per mL.
Interpretation No UNAIDS 90-90-90 targets had been met in our study population. Major campaigns are needed to 
increase HIV testing, especially among men, and to ensure all HIV-positive patients are taking ART.
Funding Centers for Disease Control and Prevention and the US Presidents Emergency Plan for AIDS Relief 
(PEPFAR).
Introduction
Antiretroviral therapy (ART) prevents HIV transmission,1 
and in the HPTN052 study,2 provided 96% protection 
against transmission when the HIV-positive partner in a 
couple was treated. In another study of 767 HIV-
serodiscordant couples who did not use condoms, no 
HIV transmissions occurred when the HIV-positive 
person was taking ART and had achieved viral 
suppression.3 Undetectable HIV RNA reflects successful 
treatment, improved individual health, and correlates 
with reduced HIV transmission.4 Giving more HIV-
positive people ART is expected to reduce HIV incidence 
at a population level. In an area of KwaZulu-Natal, South 
Africa, every 1% increase in coverage of ART has reduced 
HIV incidence by 1·1%.5
Aiming to end the AIDS epidemic worldwide, UNAIDS 
has set ambitious targets of having 90% of people living 
with HIV knowing their HIV status, 90% of people 
diagnosed as having HIV receiving sustained ART, and 
90% of people receiving ART having viral suppression by 
2020.6 When these targets are met, 73% of all HIV-positive 
people would have viral suppression, which, according to 
modelling, would end the AIDS epidemic by 2030.6 
Delivery of medical care to HIV-positive people requires 
a sequence of diagnostic tests, treatment with ART, and 
monitoring of viral load: the HIV linkage to care and 
treatment cascade.7,8
In South Africa, the HIV epidemic has substantial 
geographical variation, with KwaZulu-Natal having the 
highest burden and a provincial HIV prevalence in 
pregnant women of 40% (95% CI 38–42). By contrast, 
in the Northern Cape, the province with the lowest 
burden, antenatal HIV prevalence was less than half of 
that in KwaZulu-Natal (18%, 95% CI 15–20). In addition 
to provincial variation, there is much heterogeneity at 
district level. Within KwaZulu-Natal, antenatal HIV 
prevalence varies from 46% (the highest nationally) in 
iLembe to 33% in Amajuba, although in all 12 districts in 
KwaZulu-Natal, HIV prevalence exceeds 30%.9
Despite 1·8 million people taking ART in South Africa, 
the high number of people needing treatment means that 
coverage is low (52% in 2011).10 South Africa expanded 
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access to ART by changing the eligibility criteria from a 
CD4 count less than 200 cells per µL to a count less than 
350 cells per µL in 2013,11 and again in 2015, after this 
study had started, to less than 500 cells per µL.12 We 
assessed the HIV linkage to care and treatment cascade 
among participants enrolled in the HIV Incidence 
Provincial Surveillance System (HIPSS), a multilevel 
community-based survey, in KwaZulu-Natal, South Africa. 
We aimed to identify the points in the cascade where 
patients are lost to care, preventing them from achieving 
continuous HIV treat ment and viral suppression.
Methods
Study design and population
The design of HIPSS has been described elsewhere.13 
Briefly, a three-stage sampling design was used to 
randomly select a household-based representative sample 
of 10 000 individuals in two cross-sectional surveys 
(appendix). In the first stage, 212 enumeration areas used 
for the national census were drawn randomly. In the 
second stage, from each enumeration area 50 households 
were drawn systematically along a serpentine pattern 
from a random start point. These households were 
approached, and if a household refused, the house next to 
it was approached instead. In the third stage, one member 
of each selected household was selected at random. For 
this analysis, we used data from a HIPSS cross-sectional 
survey done from June 11, 2014, to June 22, 2015, in 
Vulindlela and Greater Edendale in uMgungundlovu 
District, central KwaZulu-Natal, where the HIV prevalence 
among pregnant women was 42% (95% CI 35–51)—one 
of six districts in South Africa with antenatal HIV 
prevalence greater than 40%.9 The estimated population 
in the study area was 117 976 men and 126 723 women; 
48% of the population was male.
Eligible participants were men and women aged 
15–49 years residing in the selected households who 
were willing to participate and undergo study 
procedures, and could provide written informed consent 
in either English or Zulu (or parental consent with 
assent if participants were <18 years). We excluded 
individuals who did not have the mental capacity to 
provide consent or who were planning to relocate within 
12 months.
Selected individuals were interviewed by fieldworkers 
with use of a standardised questionnaire with closed-
ended questions about demographic and socioeconomic 
char acteristics, behavioural and medical information, 
HIV status, sexual risk behaviour, and access to health 
care. Women were also asked about childbearing history 
and access to prevention of mother-to-child transmission 
services, and men were additionally asked about circum-
cision status.
Participants provided plasma, urine, and genital swab 
samples to allow testing for HIV, sexually transmitted 
infections, and pregnancy. HIV testing was done with 
fourth generation EIAs,14 with HIV antibodies and antigens 
measured by the Biomérieux Vironostika Uniform II 
Antigen/Antibody Microelisa system (BioMérieux, Marcy 
I’Etoile, France) and HIV 1/2 Combi Roche Elecsys (Roche 
Diagnostics, Penzberg, Germany). Positive samples were 
confirmed with an HIV-1 western blot assay (Bio-Rad 
Laboratories, Redmond, WA, USA). Individual HIV-1 RNA 
viral load measurements were tested with Roche COBAS 
Ampliprep/ COBAS TaqMan HIV-1 version 2.0 assay 
(TaqMan, Roche Diagnostics, Mannheim, Germany). In 
HIV-positive participants, CD4 cell counts were done with 
flow cytometry (BD FACSCalibur, BD Biosciences, 
San Jose, CA, USA) and viral load was measured with the 
COBAS AmpliPrep/COBAS TaqMan HIV-1 version 2.0 
Research in context
Evidence before this study
In 2014, UNAIDS proposed their 90-90-90 HIV testing and 
treatment targets for 2020. We searched PubMed with the 
search terms “90-90-90”, “HIV”, and “Africa” for all English-
language papers reporting on these targets published from 
Jan 1, 2014, to May 31, 2016. Measuring the progress towards 
achieving these targets, however, is difficult. Most available 
data are not based on population-based random surveys and, 
therefore, do not provide unbiased population-level estimates. 
Rather, most information is derived from model-based 
estimates, self-reported HIV status, or data collected routinely 
in clinics. 
Added value of this study
The first target, knowledge of HIV status, can only be measured 
in a population-based study and not with clinic-based data. The 
last target, viral suppression, cannot be based solely on patients 
attending ART clinics because it excludes patients who start 
ART but in whom viral load has not been assessed. Our study 
overcame both these issues. We used data from a multilevel 
community survey to measure directly population-level 
knowledge of HIV status, use of ART, and viral suppression 
(based on self-reports and laboratory testing) to assess progress 
towards achieving the 90-90-90 targets in an area with a high 
HIV burden. The UNAIDS 90-90-90 targets were not met in our 
study population, mainly owing to lack of knowledge of HIV 
status, especially among men. The target best achieved was 
viral suppression by ART. 
Implications of all the available evidence
It is unlikely that the UNAIDS 90-90-90 targets will be met in 
most high-burden countries and areas by 2020. Some isolated 
countries (eg, Botswana) or communities might reach these 
targets, but other countries, such as Kenya, are far from doing 
so. Major campaigns are needed to increase the prevalence of 
HIV testing, especially among men.
See Online for appendix
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assay. Testing for presence of ART (nevirapine, efavirenz, 
lamivudine, emtricitabine, zidovudine, lopinavir, tenofovir) 
was done by high-performance liquid chromatography 
coupled to tandem mass spectrometry in HIV-positive 
participants who had high viral loads (>10 000 copies per 
mL) but who reported taking ART or in individuals who 
had un detectable viral loads but reported not taking ART.
Ethics approval for HIPSS was provided by the 
University of KwaZulu-Natal biomedical research ethics 
committee (BF269/13) on May 13, 2014, and the US 
Centers for Disease Control and Prevention in col-
laboration with the Department of Health, Province of 
KwaZulu-Natal (HRKM 08/14). Participants gave written 
informed consent before enrolment.
Statistical analysis
The sample for this study consisted of all participants 
enrolled in the HIPSS survey who provided peripheral 
blood samples for HIV testing and completed interview 
questions. The elements of the UNAIDS 90-90-90 
treatment cascade were assessed in the following ways: 
the numerator for HIV status was the number of 
participants who had positive HIV tests and self-reported 
in the survey that they were HIV positive during the 
interview, and the denominator was the number of 
participants who tested HIV positive in the survey; for 
receipt of sustained ART, the numerator was the number 
of participants who self-reported using ART in the 
interview and the denominator was the number of 
participants with laboratory confirmed HIV and who 
reported knowing they were HIV positive in the interview; 
for viral suppression, the numerator was the number of 
participants who self-reported using ART in the interview 
and had laboratory confirmed HIV RNA viral loads less 
than 1000 copies per mL, and the denominator was the 
number of participants who self-reported using ART. For 
receipt of sustained ART, we also did an analysis in which 
participants with laboratory confirmed presence of 
ART were included in the numerator. All participants 
who reported using ART were assumed to be retained in 
the cascade of care. Participants were classified as being 
linked to care if they reported receiving at least one of 
home-based care, a CD4 cell count, viral-load testing, and 
ART or treatment of opportunistic infections. We defined 
HIV-positive participants as those who tested positive in 
samples provided for this study.
To account for the complex multilevel sampling design, 
weighted proportions and SEs were analysed with SAS 
Figure 1: HIV status by laboratory testing, knowledge of HIV status, CD4 cell counts, ART status, and viral load suppression status
Calculations were weighted; due to rounding the sum of some population numbers do not equal the total on the previous level. ART=antiretroviral therapy. *One viral load missing.  
9812 participants interviewed and tested for HIV (population 244 699)
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(version 9.4) survey procedures (appendix). Weights took 
into account the probability of selecting the enumeration 
area, the household in the enumeration area, and the 
individual in the household, then were adjusted for non-
response and benchmarked to the size of the population in 
the study area. For comparisons of weighted proportions, 
we calculated p values with the Rao-Scott χ² statistic, a 
design-adjusted version of the Pearson χ² statistic, using a 
design correction based on the design effects of the 
proportions, which involved differ ences between observed 
and expected frequencies.15,16 Estimates used a weighted 
likelihood function, weighted first derivatives, and the 
Newton-Raphson algorithm to find the coefficient 
estimates that maximised the weighted pseudolikelihood. 
We used the Taylor series method to estimate SEs of 
proportions and design-based CIs and test statistics. 
Descriptive statistics, such as population-weighted 
percentages, were weighted and are cited with 95% CIs. 
Unweighted counts are also presented.17 Multivariate 
logistic regression was done to investigate factors 
associated with meeting each of the steps of the cascade.
Role of the funding source
The funders of the study played a role in the study design, 
data interpretation and writing of the report, but not in 
data collection or data analysis. The corresponding 
author had full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Results
Of 14 618 households approached for the HIPSS survey, 
11 289 agreed to participate. 10 389 households (92%) had 
eligible participants, 577 (6%) of whom refused to 
participate. Thus, 9812 participants were enrolled in 
HIPSS and tested for HIV (figure 1), of whom 3547 (36%) 
were men and 6265 (64%) were women (table 1).
3969 of 9812 people overall were confirmed to be HIV 
positive (36%, 95% CI 35–38). The population-weighted 
HIV prevalence for men was 28% (95% CI 26–30, 1014 of 
3547) and for women was 44% (42–46, 2955 of 6265, 
p<0·0001). Thus, we estimate that 33 045 HIV-positive 
men and 55 881 HIV-positive women aged 15–49 years 
were living in the overall study area. 31% of men (95% CI 
29–33, 1221 of 3547) and 18% of women (16–20, 1326 of 
6265) self-reported never having been tested for HIV. 
52% of men (49–54, 1719 of 3547) and 52% of women 
(50–54, 2989 of 6265) reported being HIV negative. The 
remainder of participants (85 women and 105 men) 






Married or living together 857 (14%) 241 (8%)
Single 5408 (86%) 3306 (92%)
Age group (years)
15–19 958 (18%) 658 (20%)
20–24 1266 (20%) 814 (21%)
25–29 1087 (18%) 602 (18%)
30–34 833 (14%) 461 (14%)
35–39 760 (12%) 405 (12%)
40–44 660 (10%) 320 (9%)
45–49 701 (9%) 287 (7%)
Education 
No schooling or before primary 265 (3%) 153 (3%)
Primary (grade 1–7) 375 (6%) 232 (7%)
Incomplete secondary (grade 8–11 
or NQF level 3)
2674 (45%) 1547 (47%)
Completed secondary (grade 12 or 
NQF 4)
2603 (41%) 1406 (38%)
Tertiary (diploma/degree) 345 (5%) 207 (5%)
No response 3 (<0·5%) 2 (<0·6%)
African origin 6257 (>99%) 3545 (>99%)
Ever diagnosed with an STI 318 (6%) 231 (8%)
Ever had sex 5447 (86%) 2855 (81%)
Away from home for >1 month in 
the past 12 months
623 (10%) 398 (11%)
Ever been pregnant 4391 (71%) NA
NQF=National Qualifications Framework. STI=sexually transmitted infection. 
NA=not applicable. 
Table 1: Baseline characteristics of enrolled participants
Men Women All
Number Population Proportion  
(95% CI)
Number Population Proportion 
(95% CI)
Number Population Proportion 
(95% CI)
Received nutritional support 173 6440 37% (29–44) 598 13 247 36% (31–41) 771 19 687 36% (31–41)
Had a treatment buddy 123 4116 23% (16–31) 422 7764 21% (18–25) 545 11 880 22% (18–26)
Home-based care 47 2109 12% (6–18) 182 3504 10% (7–12) 229 56 13 10% (8–13)
Had a CD4 cell count 453 15 918 90% (87–93) 1679 33 830 93% (91–94) 2132 49 748 92% (90–94)
Received a viral-load test 380 13 402 76% (71–81) 1409 28 171 77% (74–81) 1789 41 573 77% (74–80)
Treatment of opportunistic infections 155 5326 30% (25–36) 485 11 007 30% (27–34) 640 16 333 30% (27–34)
Linked to care* 488 16 806 95% (93–97) 1762 35 065 96% (95–97) 2250 51 870 96% (95–97)
*Self-reported home-based care, CD4 cell count, viral-load test, or treatment of opportunistic infection
Table 2: Numbers of participants self-reported to be HIV positive who were linked to care
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2367 of 9748 participants (22%, 95% CI 21–24) self-
reported that they were HIV positive, making the 
population-weighted prevalence 15% for men (13–17, 522 
of 3529) and 29% for women (27–31, 1845 of 6219; 
p<0·0001). The proportions of participants accurately 
self-reporting their status as HIV positive in the interviews 
were 52% of men (47–56, 504 of 1014) and 65% of women 
(62–67, 1833 of 2955; p<0·0001). Among the 1014 HIV-
positive men, 260 (23%, 19–26) self-reported to have 
never been tested and 205 (22%, 19–25) self-reported to 
have tested HIV negative in their latest HIV test (median 
time since latest test before survey 19 months, IQR 9–39). 
Among the 2955 HIV-positive women, 442 (11%, 9–13) 
self-reported to have never been tested and 618 (22%, 
20–25) self-reported to have tested HIV negative in their 
latest HIV test (median time since testing 13 months, 
IQR 5–27). The remainder of partici pants with confirmed 
HIV-positive status (45 men and 62 women) refused to 
disclose HIV status to data collectors.
Of 4930 women who had ever been tested for HIV, 3918 
(79%, 95% CI 78–81) had ever been pregnant, and among 
1326 who had never been tested, 473 (32%, 28–36) had 
ever been pregnant (p<0·0001). 38% of HIV positive 
women (35–41, 672 of 1845) also reported receiving an 
HIV test at an antenatal visit. If these women are 
removed from the analysis, 20% of women (18–23, 1326 
of 5593) had never been tested for HIV. Among women 
who had ever or never been pregnant, 8% (7–10, 3473 of 
4391) and 42% (38–46, 853 of 1865), respectively, had 
never been tested for HIV.
Among participants who knew their HIV-positive status, 
almost all were linked to care (table 2, figure 2, appendix). 
The services accessed by most participants were CD4 cell 
counts and viral load testing (table 2).
Only 69% of men (95% CI 63–75, 344 of 522) and 
70% of women (68–73, 1254 of 1845) who knew they were 
HIV positive were taking ART (p=0·71) and, respectively, 
among these only 5% (3–7, 32 of 522) and 5% (4–6, 97 of 
1845) reported being told by a nurse or doctor that they 
needed ART but were not currently receiving treatment. 
Of all HIV-positive participants, irrespective of CD4 cell 
count or knowledge of HIV status, 1592 of 3969 (42%, 
95% CI 40–45) reported taking ART. Among those with 
confirmed HIV-positive status, 341 of 1014 men (37%, 
32–41) and 1251 of 2955 women (46%, 43–48) were taking 
ART (p=0·0004). When laboratory results for the 
presence of ART were included, the percentage of HIV-
positive participants receiving ART remained similar 
(36% of men, 31–40, 331 of 1014, and 46% of women, 
43–48, 1251 of 2955; p<0·0001).
Considering CD4-cell-count thresholds for starting 
ART, 74% of men (95% CI 66–82, 144 of 215) and 65% of 
women (59–71, 239 of 404) who had CD4 counts less than 
350 cells per µL reported taking ART. Similarly, 75% of 
men (69–81, 226 of 330) and 66% of women (62–71, 506 
of 802) who had CD4 counts less than 500 cells per µL 
reported taking ART.
Among HIV-positive participants, 2107 of 3969 (53%, 
95% CI 50–56) had viral loads less than 1000 copies per 
mL, irrespective of ART status, with prevalence being 
44% (39–49, 427 of 1014) among men and 58% (55–61, 
1680 of 2955) among women (p<0·0001). Among 
participants who reported taking ART, the proportion 
with viral loads less than 1000 copies per mL was not 
significantly different between men and women (85%, 
80–90, 294 of 341 vs 90%, 87–92, 1117 of 1249; p=0·12). 
When laboratory results for the presence of ART were 
included, the percentages become 89% (85–94, 298 of 
331) and 92% (90–94, 1156 of 1248), respectively (p=0·28). 
20% of men (16–24, 133 of 669) and 32% of women 
(29–36, 563 of 1697) who were HIV positive and did not 
report taking ART had suppressed viral loads (p<0·0001).
For the first target of the UNAIDS 90-90-90 cascade, 
knowledge of HIV-positive status, attainment in men 
and women was much lower among people younger 
than 25 years than among those in older age groups 
(figure 3, appendix), and for the second element, people 
who are HIV positive taking ART, attainment was lowest 
for participants aged 20–24 years. The third element of 
suppressed viral load was achieved in high proportions 
of all age groups.
Factors significantly associated with attainment of the 
overall UNAIDS 90-90-90 targets included female sex, 
being married or cohabitating, and age 35 years or older 
(table 3). The same variables were also signifi cantly 
associated with improved attainment of the first target, 
which is unsurprising because this target largely affects 
overall target achievement.
Discussion
None of the UNAIDS 90-90-90 targets for diagnosis, 
treatment, and viral suppression were met among 
HIV-positive participants in our study population. 














































Elements of the 90-90-90 cascade
Figure 2: Cascade of care in participants
Percentages are based on the number of HIV-positive people and are population weighted. Absolute numbers for 
each element are available in the appendix. ART=antiretroviral therapy.*Subset of the element or elements to the 
left. †Denominator includes HIV-positive people with suppressed viral loads, irrespective of ART status. 
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having suppressed viral load. This target had also been 
achieved in 85% of men. By contrast, only 52% of HIV-
positive men and 65% of HIV-positive women knew 
their status, and, of those, 69% and 70%, respectively, 
reported receiving ART. Only 44% of HIV-positive men 
and 58% of HIV-positive women had viral loads less 
than 1000 copies per mL. The largest shortfall in the 
linkage to care and treatment cascade, therefore, was the 
first target, which is the entry point to the health-care 
system.
Figure 3: HIV cascade by age group
(A) People living with HIV who know they are HIV positive. (B) People who know they are HIV positive and are taking ART. (C) HIV-positive people taking ART with 
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UNAIDS has estimated that only 45% of people living 
with HIV in sub-Saharan Africa know their status.6 In 
our study 60% of HIV-positive participants knew their 
status. Among HIV-infected populations in other 
countries, 83% in Botswana in 2013–15,18 77% in Malawi 
in 2013,19 59% in Kenya in 2012,20 and 67% in Swaziland21 
have been reported to know their HIV status. A small 
study in Cape Town, South Africa, in 2010 showed that 
55% of HIV-positive people knew their HIV status.22 
When separated by sex, 52% of HIV-positive men and 
65% of HIV-positive women in our study reported 
knowing they were HIV positive. Shisana and col-
leagues23 found even lower pro portions in South Africa 
in 2012 (38% of HIV-positive men and 55% of HIV-
positive women). In Zambia in 2011–12, 52% of men 
reported ever having been tested for HIV.24 Older studies 
have generally reported poorer knowledge of HIV status, 
which suggests that availability of HIV testing has 
increased over time. Botswana is the sub-Saharan 
country with the highest frequency of HIV diagnosis, 
reasons for which include high rates of testing in 
pregnant women and a policy of routine opt-out testing 
in health-care settings since 2004.18
Once people in the KwaZulu-Natal district in our study 
knew they were HIV positive, linking to the care and 
treatment cascade was good, with more than 90% having 
had CD4 cell counts and more than 95% having ever 
linked to care. The results for the second UNAIDS 
90-90-90 target, therefore, were 69% of men and 70% of 
women receiving ART. By contrast, in Swaziland, 50% of 
HIV-positive participants were linked to care.21
42% of all HIV-positive people in this study (37% of 
men and 46% of women) reported taking ART, which is 
higher than the UNAIDS estimate of 39% of people 
living with HIV in sub-Saharan Africa.6 Additionally, 
Shisana and colleagues23 reported that 31% of 
HIV-positive people in South Africa (26% men and 
35% women) were taking ART, and Takuva and 
colleagues25 estimated that 34% were receiving ART. The 
PopART study26 found that 52% and 49% of HIV-positive 
people were taking ART in an area of the Western Cape 
province of South Africa and in Zambia, respectively. 
Other studies found that 63% of HIV-positive people in 
Malawi19 and 40% in Kenya20 were taking ART. Variability 
in coverage is seen across the entire continent with, for 
example, coverage of 41% in eastern and southern Africa, 
23% in western and central Africa, and 19% in north 
Africa.6 One reason for the low ART coverage in most 
sub-Saharan African countries is the decision to give 
patients ART based on CD4 cell counts, meaning that 
many people diagnosed as having HIV were linked to 
care but ART was not started. Most countries are 
implementing test-and-treat systems, meaning that ART 
is started irrespective of CD4 cell count. The number of 
HIV-positive individuals taking ART is, therefore, 
expected to increase.
Viral load suppression was seen in 44% and 58% of 
HIV-infected men and women, respectively, in this study, 
which is substantially below the UNAIDS target of 73%. 
In sub-Saharan Africa, the proportion of people living 
with HIV with suppressed viral loads is estimated to be 
29–32%.6,27 In Swaziland in 2011 the proportion was 35%,21 
in Botswana in 2013–15 it was 70%,18 in Kenya in 2012 it 
was 40%,20 and in South Africa in 2012 it was 25%.25 
Thus, despite high prevalence in the district in South 
Africa that we assessed, viral suppression was achieved 
People with HIV who 
know their status
Taking ART* Suppressed viral load† Overall suppressed 
viral load‡ 
Sex (women vs men) 2·12 (1·75–2·57) 1·17 (0·86–1·58) 1·60 (0·92–2·77) 2·11 (1·69–2·63)
Marital status (married or living together vs single) 1·51 (1·12–2·04) 1·09 (0·81–1·48) 1·13 (0·56–2·27) 1·50 (1·08–2·09)
Age (years)
15–19 vs 45–49 0·16 (0·09–0·29) 0·82 (0·27–2·51) 0·27 (0·07–1·13) 0·22 (0·13–0·38)
20–24 vs 45–49 0·31 (0·20–0·47) 0·37 (0·23–0·61) 0·28 (0·12–0·68) 0·23 (0·16–0·34)
25–29 vs 45–49 0·62 (0·41–0·93) 0·44 (0·27–0·72) 0·60 (0·23–1·58) 0·32 (0·24–0·44)
30–34 vs 45–49 0·94 (0·67–1·33) 0·68 (0·44–1·03) 0·47 (0·21–1·05) 0·51 (0·37–0·70)
35–39 vs 45–49 1·22 (0·85–1·75) 0·91 (0·57–1·44) 0·48 (0·21–1·09) 0·76 (0·53–1·08)
40–44 vs 45–49 1·21 (0·82–1·78) 1·10 (0·67–1·83) 1·00 (0·45–2·23) 0·94 (0·65–1·36)
Education
Completed secondary 0·84 (0·57–1·22) 0·82 (0·48–1·39) 1·35 (0·67–2·72) 1·05 (0·74–1·50)
Incomplete secondary 1·44 (0·97–2·15) 0·82 (0·50–1·34) 1·03 (0·55–1·94) 1·19 (0·80–1·75)
No schooling 0·58 (0·32–1·05) 0·65 (0·30–1·41) 6·26 (1·39–28·27) 1·06 (0·61–1·85)
Primary schooling (ref) 1 1 1 1
Away from home for >1 month in past 12 months 
(no vs yes)
1·00 (0·74–1·36) 0·95 (0·66–1·38) 1·81 (1·13–2·91) 1·29 (0·96–1·73)
ART=antiretroviral therapy. *Among HIV-positive people who know their status. †Among HIV-positive people taking ART. ‡Irrespective of ART status or knowledge of HIV 
status (among all HIV-positive people).
Table 3: Multivariate odds ratios and 95% CIs for associations between sociodemographic variables and the three elements of the UNAIDS 90-90-90 goals
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in more people than in most other countries in the 
region. This finding can be partly attributed to our survey 
being done more recently than the other studies, because 
HIV diagnosis and ART coverage have improved over 
time. Additionally, many HIV-positive participants 
claimed not to be taking ART but had viral load 
suppression.
The greatest success in KwaZulu-Natal was the high 
proportions of participants taking ART who had achieved 
viral suppression, with 85% of men and 90% of women 
having viral loads less than 1000 copies per mL. These 
proportions are higher than in many developed 
countries,27 although lower than the 97% reported in 
Botswana.18 It was also much higher than the 
26% reported in rural areas of the North West province of 
South Africa.28 We assessed ART use by asking 
participants whether they were currently taking ART. In 
the analysis of viral suppression, we did not include 
patients who had started but discontinued ART. We did 
not collect information on adherence to ART, but the 
high frequency of viral suppression suggests that it is 
good. ART is available free of charge at clinics close to 
where many people in the study area live. The public 
health system mandates monitoring of viral load to 
assess treatment success and detect issues with 
adherence, along with steps to be taken when patients 
stop taking treatment.29 These steps include comprehen-
sive adherence counselling, repeated viral-load testing, 
and switching to second-line treatment.12
None of the three UNAIDS 90-90-90 cascade targets 
had been met in the population we assessed. If service 
coverage is not increased, South Africa will not be able to 
reverse the HIV epidemic in this high-burden district. 
However, the proportions of people who know their HIV 
status, are receiving ART, and have achieved viral load 
suppression are all greater than those in a representative 
sample of South Africa,23 which suggests that other 
districts face similar problems.
Knowledge of HIV status was the only target for which 
the proportion was higher in women than in men. This 
difference is driven by the testing of women during 
pregnancy. Men unaware of their HIV status are not 
linking to care, although once in care they seem to 
achieve the targets as well as women.
This study was based on a representative sample of the 
general population in the uMgungundlovu district and, 
therefore, our findings are generalisable to the whole 
study area. The greatest limitation of our study is that 
knowledge of HIV status and ART use were self-reported 
and, therefore, the data might be susceptible to bias, 
such as social desirability bias. For example, among 
79 participants who reported being HIV negative but had 
positive HIV tests and were selected for laboratory ART 
testing, 31 tested positive for the presence of ART. If 
knowledge of HIV status was under-reported, the 
proportions of participants who knew their HIV status is 
an underestimate. Adherence to ART was not assessed 
and, therefore, we do not know whether participants who 
said they were taking ART were receiving adequate doses 
to achieve viral suppression. Finally, we only assessed 
people aged 15–49 years, meaning that the results are not 
general isable to older or younger people.
Improvement is needed in all aspects of the HIV care 
and treatment cascade, with emphasis on campaigns to 
increase HIV testing. Such campaigns should be 
strengthened by scaling-up of testing in all settings, 
especially where men and boys can be reached such as 
mobile testing in communities30 and workplace testing. 
The PopART study31 showed increased uptake of testing 
was when it was offered in peoples’ homes. For instance, 
one round of home-based testing led to an increase in 
people knowing their HIV status from 47% to more 
than 87%.Because HIV testing is done before male 
circumcision, combining HIV and circumcision cam-
paigns would be cost effective. In our study, many people 
who claimed to have been tested for HIV reported being 
HIV negative, yet they had HIV-positive results when 
tested during the study. This finding indicates the need 
for repeated testing.
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